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Current porcine reproductive and respiratory syndrome virus (PRRSV) vaccines sometimes fail 24	
to provide adequate immunity to protect pigs from PRRSV-induced disease. This may be due to 25	
antigenic differences among PRRSV strains. Rapid production of attenuated farm-specific 26	
homologous vaccines is a feasible alternative to commercial vaccines. In this study, attenuation 27	
and efficacy of a codon-pair de-optimized candidate vaccine generated by synthetic attenuated 28	
virus engineering approach (SAVE5) were tested in a conventional growing pig model. Forty 29	
pigs were vaccinated intranasally or intramuscularly with SAVE5 at day 0 (D0). The remaining 30	
28 pigs were sham-vaccinated with saline. At D42, 30 vaccinated and 19 sham-vaccinated pigs 31	
were challenged with the homologous PRRSV strain VR2385. The experiment was terminated at 32	
D54. The SAVE5 virus was effectively attenuated as evidenced by a low magnitude of SAVE5 33	
viremia for 1-5 consecutive weeks in 35.9% (14/39) of the vaccinated pigs, lack of detectable 34	
nasal SAVE5 shedding and failure to transmit the vaccine virus from pig to pig. By D42, all 35	
vaccinated pigs with detectable SAVE5 viremia also had detectable anti-PRRSV IgG. Anti-IgG 36	
positive vaccinated pigs were protected from subsequent VR2385 challenge as evidenced by lack 37	
of VR2385 viremia and nasal shedding, significantly reduced macroscopic and microscopic lung 38	
lesions and significantly reduced amount of PRRSV antigen in lungs compared to the non-39	
vaccinated VR2385-challenged positive control pigs. The nasal vaccination route appeared to be 40	
more effective in inducing protective immunity in a larger number of pigs compared to the 41	
intramuscular route. Vaccinated pigs without detectable SAVE5 viremia did not seroconvert and 42	
were fully susceptible to VR2385 challenge. Under the study conditions, the SAVE approach 43	
was successful in attenuating PRRSV strain VR2385 and protected against homologous virus 44	
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challenge. Virus dosage likely needs to be adjusted to induce replication and protection in a 45	
higher percentage of vaccinated pigs.     46	
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1. Introduction  47	
Porcine reproductive and respiratory syndrome virus (PRRSV) is widespread in the 48	
global pig population and associated with reproductive failure in adult pigs and respiratory 49	
disease in growing pigs [1] resulting in estimated annual losses of $664 million to the U.S. swine 50	
industry [2]. PRRSV is an enveloped, positive-sense, single-stranded RNA virus [3;4] that 51	
belongs to the family Arteriviridae in the order Nidovirales [4]. The PRRSV genome contains 52	
eight structural protein open reading frames (ORFs) and a few non-structural protein ORFs [5] 53	
and isolates can be divided into two main genotypes: type 1 (European type), and type 2 (North 54	
American type) [6]. Mutations such as insertions or deletions occur frequently in the PRRSV 55	
genome making it one of the most genetically diverse pig viruses [7].  56	
The enormous continual change and diversity of PRRSV strains has resulted in limited 57	
efficacy of current commercial vaccines and vaccination strategies [8]. Modified live-attenuated 58	
virus vaccines (MLVs) are the most effective option currently available to control clinical signs 59	
associated with PRRSV infection; however, while these vaccines in general protect pigs well 60	
against homologous challenge they are not always capable of eliciting protective immunity 61	
against heterologous field strains [9]. Due to limited vaccine homology with circulating field 62	
strains on some farms, pig producers often rely on planned exposure to the pathogenic farm 63	
strain [10] which is risky and may not always be economically beneficial or acceptable from an 64	
animal welfare point of view. Therefore, rapid attenuation of PRRSV would afford an 65	
opportunity to quickly generate farm-specific vaccines. 66	
Recently the synthetic attenuated virus engineering (SAVE) approach was utilized to 67	
rapidly attenuate the wild-type PRRSV isolate VR2385 [11]. Specifically, the codon-pairs of the 68	
major envelope GP5 gene of PRRSV were deoptimized through a computer algorithm which 69	
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resulted in a modified GP5 nucleotide sequence while retaining the original amino acid 70	
sequence. The resulting virus was designated SAVE5. When SAVE5 was tested in vitro it was 71	
genetically stable. Experimental infection of pigs resulted in lower levels of viremia and reduced 72	
macroscopic and microscopic lung lesions compared to the wild-type VR2385 virus [11]. The 73	
protective efficacy of the SAVE5 was unknown. In the present study, the immunogenicity and 74	
protective efficacy of SAVE5 in decreasing clinical signs, lesions and viremia associated with 75	
wild-type PRRSV challenge were assessed using a conventional pig model. 76	
 77	
2. Methods 78	
2.1. Animals and housing 79	
The experimental protocol was approved by the Iowa State University Institutional 80	
Animal Care and Use Committee (14-D-0008-A). Sixty-eight, 2-week-old, commercial crossbred 81	
pigs from a PRRSV-free source herd were transported to the Livestock Infectious Disease 82	
Isolation Facility at Iowa State University, Ames, Iowa, USA. The study was done in two 83	
replicates 12 months apart. The same source herd was used for both replicates. Upon arrival, the 84	
pigs were randomly assigned to one of five groups. Initially and for each replicate, vaccinated 85	
pigs were housed in one room and the sham-vaccinated pigs were housed in another room. Prior 86	
to virus challenge, the pigs were further separated by treatment status into four (Replicate 1) or 87	
three (Replicate 2) rooms with one pen in each room. Pigs were given continuous access to age 88	
appropriate feed (Nature’s Made, Heartland Co-op, Cambridge, Iowa, USA) and water. 89	
 90	
2.2. Experimental design  91	
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The experimental groups are outlined in Table 1. At day 0 (D0) when the pigs were 3 92	
weeks old, VAC-IM-CONTROL, VAC-IM-PRRSV and VAC-IN-PRRSV were vaccinated with 93	
the SAVE5 candidate vaccine and the NEG-CONTROL and POS-CONTROL groups were 94	
sham-vaccinated with saline. The intramuscular (IM) route was used for the VAC-IM-95	
CONTROL, VAC-IM-PRRSV, NEG-CONTROL and the POS-CONTROL groups and the 96	
intranasal (IN) route was used for the VAC-IN-PRRSV group. At D42, pigs were challenged 97	
with the homologous PRRSV strain VR2385 (VAC-IM-PRRSV, VAC-IN-PRRSV, POS-98	
CONTROL) or were sham-inoculated with saline (VAC-IM-CONTROL, NEG-CONTROL). All 99	
pigs were necropsied at D54. Blood samples were collected weekly from D0 through D42 and on 100	
D44, D46, D48, D51 and D54. The blood was centrifuged at 3000 g for 10 min and the serum 101	
was stored at -80°C until testing. Nasal swabs were taken from each pig on D7, D14, D21, D28, 102	
D35, D42, D44, D46, D48, D50 and D53, placed into 1 ml of saline and stored at -80°C until 103	
testing. The pigs were weighed on D0, D42 and D54.  104	
 105	
2.3. Vaccination 106	
A previously described vaccine candidate, the SAVE5 virus, was utilized [11]. At 3 107	
weeks of age, the VAC-IM-CONTROL and the VAC-IM-PRRSV groups received 3 ml of 108	
SAVE5 virus at a dose of 104.5 TCID50/ml intramuscularly into the right neck. The VAC-IN-109	
PRRSV group received 3 ml of SAVE5 virus at a dose of 104.5 TCID50/ml intranasally by slowly 110	
dripping the inoculum into the nostrils. The NEG-CONTROL and the POS-CONTROL groups 111	
received 3 ml of saline intramuscularly into the right neck. 112	
 113	
2.4. Challenge 114	
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At 9 weeks of age (D42 post-vaccination), POS-CONTROL, VAC-IM-PRRSV and 115	
VAC-IN-PRRSV groups were challenged intranasally with 106.6 TCID50 of PRRSV VR2385 by 116	
slowly dripping 1 ml of inoculum into each nostril. The NEG-CONTROL and the VAC-IM-117	
CONTROL groups were similarly sham-challenged with 1 ml of saline. 118	
 119	
2.5. Clinical evaluation 120	
On D42, D44, D46, D48, D50 and D53, rectal temperatures were taken and respiratory 121	
scores were evaluated [12]. The respiratory scores included 0=normal, 1=mild 122	
dyspnea/tachypnea when stressed, 2= mild dyspnea/tachypnea at rest, 3= moderate 123	
dyspnea/tachypnea when stressed, 4= moderate dyspnea/tachypnea at rest, 5= severe 124	
dyspnea/tachypnea when stressed and 6= severe dyspnea/tachypnea at rest [12]. 125	
 126	
2.6. Serology  127	
All serum samples were tested for PRRSV specific IgG antibodies using the IDEXX 128	
PRRS X3 Ab ELISA (IDEXX Laboratories, Inc.) according to the manufacturer’s instructions. A 129	
sample-to-positive (S/P) ratio greater than 0.4 was considered positive. A fluorescent focus 130	
neutralization (FFN) assay for determination of amount of PRRSV-specific neutralizing 131	
antibodies was done on sera collected on D42 according to protocols routinely performed at the 132	
Veterinary Diagnostic Laboratory at Iowa State University. The PRRSV strain used was type 2 133	
PRRSV strain ISU-P. In addition, FFN on D42 samples were also done at the Animal Disease 134	
Research and Diagnostic Laboratory at South Dakota State University using the VR2332 PRRSV 135	
type 2 strain. These strains are routinely used for client submissions regardless of the PRRSV on 136	
farm.  137	




2.7. RNA extraction and real-time PCR  139	
Total nucleic acids from serum and nasal swabs were extracted using the KingFisher Flex 140	
96-tip comb (Thermo Scientific) and the MagMax-96 viral RNA isolation kit (Life 141	
Technologies) [13]. Positive and negative controls were included on each plate. Extracted 142	
samples were tested by quantitative reverse transcriptase (RT) PCR for the presence and amount 143	
of PRRSV RNA [14]. The threshold was set at 0.05 with a cycle threshold (CT) of less than 37 144	
cycles considered positive.  145	
 146	
2.8. Characterization of the PRRSV strains detected by differential real-time RT-PCR 147	
To differentiate the vaccine candidate SAVE5 and the wild type PRRSV VR2385, a 148	
duplex differential real-time RT-PCR was established based on the alignment of GP5 gene. The 149	
VR2385 primers and probe were PRRS2385F: 5’-GTGCCCTGGCTGCGTTGAT-3’, 150	
PRRS2385R: 5’-CAACGATAGAGTCTGCCCTTAGTGTC-3’, PRRSprob2385: FAM-5’-151	
CTTCGTCATTAGGCTTGCGAAGAATTGC-3’-BHQ1. The SAVE5 primers and probe were 152	
PRRSSAVEF: 5’-GCTGATTTACAACTTGACGCTATGTG-3’, PRRSSAVER: 5’-153	
GACAGGAAAAATGACAAAGCACTCG-3’, PRRSprobSAVE: CAL-Fluor®-Orange-560-5’-154	
TAACGGTACCGACTGGCTTGCGAATAAG-3’-BHQ1. The real-time RT-PCR was carried 155	
out in 96-well plates, with each reaction consisting of a total volume of 25 µl, containing 12.5 µl 156	
TaqMan One-Step RT-PCR master mix reagent (Applied Biosystems), 6 µl RNA, 0.625 µl 40× 157	
MultiScribe and RNase Inhibitor, 1 µl each of the two primers (10 µM), 0.5 µl probe (10 µM) 158	
and 3.375 µl RNase-free water. Amplification reactions were performed using an Applied 159	
Biosystems 7500 Fast Real-Time PCR System (Applied Biosystems) under universal conditions: 160	
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30 min at 50°C, 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. A 161	
sample was considered negative if no signal was detected during 40 amplification cycles. 162	
PRRSV ORF5 was sequenced from two PRRSV RT-PCR positive pigs in each of the 163	
VAC-IM-PRRSV, VAC-IN-PRRSV and the POS-CONTROL groups on D54. In addition, the 164	
SAVE5 vaccine strain and the VR2385 challenge strain used for inoculation were also 165	
sequenced. PRRSV ORF5 amplification was performed using primers GP5F (5′-166	
ATGTTGGGGAAATGCTTGACCG-3′) and GP5R (5′-CTAAGGACGACTCCATTGTTCCG-167	
3′) [13]. The PCR products were sequenced using a 3730xl DNA Analyzer at the Iowa State 168	
University DNA Facility, Ames, Iowa, USA. 169	
 170	
2.9. Necropsy  171	
All pigs were humanely euthanized on D54 by intravenous injection of pentobarbital 172	
sodium overdose (Fatal Plus®, Vortech Pharmaceuticals, LTD, Dearborn, Michigan, USA). A 173	
veterinary pathologist blinded to the treatment groups of the pigs scored and recorded the 174	
severity of macroscopic lung lesions for each pig. Specifically, macroscopic lung lesions were 175	
assessed to determine the percentage of the lung affected by pneumonia [12]. Five sections of 176	
lungs, tonsil and tracheobronchial lymph nodes were fixed in 10% neutral buffered formalin and 177	
routinely processed for further histopathological analysis. 178	
 179	
2.10. Histopathology and immunohistochemistry  180	
Microscopic lesions were assessed by a pathologist blinded to the treatment groups. Lung 181	
lesions were scored for severity of PRRSV induced interstitial pneumonia lesions ranging from 182	
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0=normal to 6=severe diffuse [15]. Each pig was scored by two different pathologists and the 183	
average score was determined and used for further analysis.  184	
To assess presence and amount of PRRSV antigen, immunohistochemistry was 185	
conducted on sections of lung tissues [16]. Scores ranged from 0=no antigen detectable to 186	
3=abundant antigen diffusely distributed. All slides were independently evaluated by two 187	
pathologists and the mean score was utilized.  188	
 189	
2.11. Statistical analysis 190	
Summary statistics were calculated for groups to assess the distributional property. 191	
Quantitative RT-PCR data was log transformed prior to analysis. A generalized linear mixed 192	
model was used for all statistical comparisons with SAS version 9.3 (SAS Institute, Cary, NC) 193	
with group, time and their interaction were fixed effects and pig as random effect. A P-value of 194	
less than 0.05 was considered significant. Difference in mean response was assessed between 195	
groups. Protection was assessed by regrouping pigs in the VAC-IM-PRRSV and VAC-IN-196	
PRRSV groups by seroconversion to PRRSV (S/P ratio greater than 0.4) at challenge (D42) into 197	
VAC-D42-POS (n=10) and VAC-D42-NEG (n=20) pigs (Table 2). These two groups were 198	
directly compared to the POS-CONTROLS. Area under the curve viremia (AUC) was calculated 199	
for each pig from D45 to D54. Correlation between AUC and antibody levels at challenge (D42) 200	
was assessed by Pearson’s correlation test.   201	
 202	
3. Results 203	
3.1. Clinical signs and weight gain 204	
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The NEG-CONTROL, the VAC-IM-PRRSV and the VAC-IN-PRRSV groups had no 205	
clinical signs of disease during the experiment. One POS-CONTROL pig had bilateral mucous 206	
discharge starting at D44 with a respiratory score of 2 by D53. Two other POS-CONTROL pigs 207	
had mucous discharge on D53. Statistical evaluation of the respiratory scores (data not shown) or 208	
the average daily weight gain (ADG, Tables 1 and 2) indicated no significant differences among 209	
the treatment groups. Differences in rectal temperatures were observed on D46 when the POS-210	
CONTROL group had statistically (P < 0.05) higher rectal temperatures compared to VAC-IN-211	
PRRSV and NEG-CONTROL groups.  212	
  213	
3.2. Seroconversion to PRRSV 214	
Mean group anti-PRRSV IgG antibody levels are summarized in Fig. 1. None of the pigs 215	
had detectable PRRSV antibodies on arrival and the NEG-CONTROL group remained 216	
seronegative until termination of the study. Vaccinated pigs developed anti-PRRSV IgG 217	
antibodies starting at D14 and VAC-IN-PRRSV pigs had significantly higher S/P ratios 218	
compared to pigs vaccinated intramuscularly at D28 (Table 3). Among vaccinated and 219	
subsequently challenged pigs only 10/30 pigs (4/20 VAC-IM-PRRSV and 6/10 VAC-IN-220	
PRRSV) pigs had seroconverted by D42 (VAC-D42-POSITIVE). There was no evidence of 221	
seroconversion in the remaining 20/30 pigs (VAC-D42-NEGATIVE; 16/20 VAC-IM-PRRSV 222	
and 4/10 VAC-IN-PRRSV). 223	
Neutralizing antibodies against PRRSV type 2 strains ISU-P or VR2332 were not 224	
detected in any of the serum samples collected at D42.  225	
 226	
3.3. PRRSV viremia and shedding 227	
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The NEG-CONTROL pigs remained PRRSV RNA negative throughout the study. 228	
PRRSV VR2385 was not detected prior to D42 in any vaccinated pig and PRRSV SAVE5 was 229	
never detected in POS-CONTROL pigs based on differential PCR and sequencing. In vaccinated 230	
pigs, SAVE5 RNA in serum samples was first detectable by D7 (Table 4). At the time of PRRSV 231	
challenge on D42, 22.5% (9/40) of the vaccinated pigs were SAVE5 viremic. After challenge, 232	
only VR2385 was detected in the VAC-IM-PRRSV group and in 3/5 viremic VAC-IN-PRRSV 233	
pigs; however, mixed SAVE5/VR2385 was detected in 2/5 viremic VAC-IN-PRRSV pigs. 234	
Prevalence rates and PRRSV loads were lower in VAC-IN-PRRSV pigs compared to POS-235	
CONTROLS which was significant on D51 (Table 4).  236	
When the D42 seropositive and seronegative subgroups were analyzed, VAC-D42-POS 237	
pigs had evidence of SAVE-replication prior to challenge whereas VAC-D42-NEG pigs did not 238	
(Fig. 2). Significant differences in amounts of VR2385 PRRSV viremia after challenge indicate 239	
that VAC-D42-POS pigs but not VAC-D42-NEG pigs were protected from VR2385 challenge 240	
(Fig. 2). There was a high correlation between AUC viremia and levels of antibody at challenge 241	
(r = -0.84 [CI -0.90, -0.73], p <0.0001) indicating that the presence of antibodies at challenge 242	
was correlated with lack of viremia after challenge.  243	
Nasal SAVE5 shedding was not detected in any of the vaccinated pigs prior to challenge. 244	
After challenge, nasal VR2385 shedding was observed in 25% (D46), 35% (D48) and 15% 245	
(D50) of the VAC-IM-PRRSV pigs; in 40% (D48) of the VAC-IN-PRRSV pigs; and in 47.3% 246	
(D46 and D48), 10.5% (D50) and 5.3% (D53) of the POS-CONTROLS. The group mean log10 247	
PRRSV genomic copy numbers in nasal swabs ranged from 3.3 to 6.8. Nasal VR2385 shedding 248	
was not detected in any of the VAC-D42-POS pigs whereas it was observed in 55% (11/20) of 249	
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the VAC-D42-NEG pigs for 1-4 consecutive days and in 47.3% (9/19) of the POS-CONTROL 250	
pigs for 1-7 consecutive days.  251	
 252	
3.4. Macroscopic lesions  253	
Gross lesion scores are summarized in Tables 1 and 2. Multifocal mottled tan areas of 254	
consolidation were found throughout the lungs of selected pigs in all PRRSV VR2385-infected 255	
groups. Challenged groups had significantly more severe lesions than the non-challenged groups 256	
(P < 0.01). The mean macroscopic lung lesions in VAC-D42-POS pigs were not significantly 257	
different from VAC-D42-NEG pigs but were significantly lower compared to the POS-258	
CONTROL (Table 2). 259	
 260	
3.5. Microscopic lesions  261	
When observed, lung lesions were characterized by mild-to-moderate multifocal 262	
lymphohistiocytic interstitial pneumonia with type 2 pneumocyte hypertrophy and hyperplasia, 263	
and increased numbers of macrophages and necrotic cellular debris in the alveolar spaces. Group 264	
mean interstitial pneumonia scores are summarized in Table 1. Overall, pigs in the VAC-IN-265	
PRRSV group had significantly less severe microscopic lesions compared to the POS-PRRSV 266	
group. When the D42 seropositive and seronegative subgroups were analyzed, VAC-D42-POS 267	
pigs had significantly lower scores compared to VAC-D42-NEG pigs and POS-CONTROL pigs 268	
(Table 2).  269	
PRRSV antigen was observed in alveolar and septal macrophages in several pigs in the 270	
PRRSV-infected groups. The amounts of detectable PRRSV antigen in VAC-IN-PRRSV pigs 271	
were significantly lower compared to the POS-CONTROL pigs (Table 1). Among VAC-D42-272	
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POS pigs, 3/10 were PRRSV IHC positive with significantly lower amounts of PRRSV antigen 273	
in lung tissues compared to VAC-D42-NEG pigs and POS-CONTROL pigs (Table 2). 274	
 275	
4. Discussion 276	
The SAVE approach to attenuate viruses requires significantly less time compared to the 277	
traditional cell culture attenuation, and most importantly the SAVE approach attenuates the virus 278	
without altering the antigenicity of the virus protein on the virion, since the protein sequence of 279	
the SAVE5 ORF5 is identical to the wild-type PRRSV ORF5. The attenuation is achieved by 280	
modification of the naturally optimized pairs of codons in a viral gene sequence without altering 281	
the codon bias or the amino acid sequence [17]. A potential drawback of the SAVE approach is 282	
over-attenuation which may affect the ability of the virus to replicate in the host. In contrast, the 283	
traditional cell culture back passage approach to attenuate viruses may introduce critical 284	
mutations in the virus genome during serial passages in cell culture, and these mutations, often 285	
only a few critical amino acid changes, contribute to virus attenuation but can also revert back to 286	
pathogenic phenotype. Therefore, there are pros and cons for both approaches.  287	
In this study, the vaccine efficacy of the PRRSV vaccine candidate SAVE5 was tested in 288	
vivo using the homologous wild-type PRRSV strain VR2385. Similar to a previous pilot study, 289	
SAVE5 virus proved to be attenuated. After vaccination, SAVE5 viremia was sporadic (< 50% 290	
of the vaccinated pigs for 1-5 consecutive weeks) and of low magnitude, SAVE5 nasal shedding 291	
was not detectable and clinical signs were absent. This further documents that codon-pair de-292	
optimization is an effective way to attenuate PRRSV. A farm-specific attenuated PRRSV 293	
vaccine could be produced via the SAVE approach in less than 2 months from PRRSV positive 294	
lung tissue or serum obtained from the farm. 295	
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In vaccinated pigs in this study, seroconversion was initially observed by D14 similar to 296	
that previously reported [11]. At challenge at D42, 30% (9/30; intramuscular route) to 60% 297	
(6/10; intranasal route) of the vaccinated pigs had detectable anti-PRRSV-IgG levels, and 20% 298	
(6/30; intramuscularly route) to 30% (3/10; intranasal route) were SAVE5 viremic. It is possible 299	
that the SAVE5 vaccine virus was too attenuated to replicate and elicit an antibody response in 300	
all of the pigs or that the vaccine virus dose used for vaccination was too low. To account for 301	
this, vaccinated pigs were further divided into VAC-D42-POS and VAC-D42-NEG groups.  302	
It is well accepted that antibodies detected in the serum shortly after infection do not 303	
necessarily correlate with protection, and that rapid induction of neutralizing antibody provides 304	
vaccine-based protection against infection [8;18]. However, a neutralizing antibody response was 305	
not detected in the present study. This may be due to antigenic differences between the viruses 306	
used in the FFN assay and the actual SAVE5 strain used. The percentage of amino acid identity 307	
of VR2385 was 92.5% for ISU-VDL strain ISU-P and 91% for the VR2332. It may also provide 308	
further evidence that detectable neutralizing antibodies may not be an ideal correlate of 309	
protection against PRRSV. Cell-mediated immunity is considered more important than 310	
neutralizing antibodies in conferring protection against PRRSV, and PRRS-specific T-cells can 311	
be observed as early as 2 weeks after infection [19]. In this pilot study cellular immunity was not 312	
assessed due to limited access to necessary reagents; however, cellular immunity needs to be 313	
addressed in future studies. In general, the best measurement of protective immunity triggered by 314	
an effective vaccine is in a challenge infection model [18]. Interestingly, VR2385 viremia and 315	
nasal shedding after challenge was not detectable in VAC-D42-POS pigs which all had 316	
seroconverted by the time of challenge. This could indicate that vaccine-induced seroconversion 317	
is associated with protection.  318	
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Under the study conditions, the nasal vaccination route appeared to be more effective 319	
resulting in protective immunity in a larger number of pigs compared to the intramuscular route. 320	
The first pig with a SAVE5 viremia was detected by D7 in the VAC-IN-PRRSV group whereas 321	
the first SAVE5 viremic VAC-IM-PRRSV pig was detected by D14. At the day of challenge 322	
60% (6/10) of the VAC-IN-PRRSV pigs had seroconverted to PRRSV in contrast to 20% (4/20) 323	
of the VAC-IM-PRRSV pigs indicating an earlier and more efficient induction of a low grade 324	
SAVE5 viremia with subsequent development of an adaptive immune response after 325	
administration of the SAVE5 vaccine strain by the intranasal route. Determination of possible 326	
differences between intramuscular and intranasal vaccination by assessing local mucosal 327	
immunity needs to be done in future.    328	
The VAC-D42-POS pigs were protected from subsequent VR2385 challenge as 329	
evidenced by lack of VR2385 viremia, VR2385 nasal shedding, significantly reduced 330	
macroscopic and microscopic lung lesions and significantly reduced amounts of PRRSV antigen 331	
in lungs compared to the non-vaccinated POS-CONTROL pigs. This indicates that the SAVE 332	
vaccine strategy may be a feasible alternative in rapidly producing a farm-specific autogenous 333	
vaccine if the immunogenicity of the SAVE vaccine can be improved. Additional experimental 334	
studies using larger number of pigs, a higher vaccine virus dose, different challenge time point 335	
post-vaccination, and heterologous PRRSV strains including concurrent infections are needed to 336	
better evaluate the benefits of this novel vaccine approach.  337	
 338	
5. Conclusions 339	
The present study further confirmed that the SAVE approach can effectively attenuate a 340	
PRRSV strain. Additional work needs to be done to further improve SAVE5 vaccine efficacy. 341	
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The ability to utilize the SAVE technology to rapidly produce, safe and efficacious, farm-342	
specific PRRSV vaccines is practical and could have a major impact on reducing the major 343	
economic losses associated with PRRSV. 344	
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Fig. 1. Group mean ELISA sample-to-positive (S/P) ratios over time in POS-CONTROL pigs 423	
(n=19), VAC-D42-NEG pigs (n=20) and in VAC-D42-POS pigs (n=10). Pigs were vaccinated at 424	
D0 and inoculated with PRRSV on D42 (arrow). An S/P ratio greater than 0.4 was considered 425	
positive. Different superscripts (A,B) indicate significantly (P < 0.05) different group means for a 426	
certain day.  427	




Fig. 2. Group mean log10 PRRSV genomic copies per ml serum over time in POS-CONTROL 429	
pigs (n=19), VAC-D42-NEG pigs (n=20) and in VAC-D42-POS pigs (n=10). Pigs were 430	
vaccinated at D0 and SAVE5-PRRSV and inoculated with PRRSV on D42. Different 431	
superscripts (A,B) indicate significantly (P < 0.05) different group means for a certain day.  432	
 433	
